An seRNA against breast cancer stops tumor growth in a xenograft breast cancer mouse model after three intravenous treatments within one week.

In the MTD study, healthy mice treated with seRNA delivered by fLNPs, showed no toxic side effects at any concentrations tested (up to 2 mg/kg), allowing multiple systemic treatments per week.

While control animals showed exponential tumor growth, seRNA-treated mice showed tumor growth inhibition and a reduction in tumor volume after just three treatments within one week.

Thus, seRNAs are not just highly selective but also highly effective in vivo, illustrating the platform character of this novel, proprietary approach.